2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

Authors’ Disclosures of Potential Conflicts of Interest
Author
Employment or
Leadership
Positions
Consultant or
Advisory Role
Stock
Ownership Honoraria
Richard F. Riedel Merck ARIAD; Novartis;
Pfizer
Robert G. Maki Bayer; Eisai;
Lilly; Novartis
Andrew J. Wagner Astex
Therapeutics (U);
EMD Serono;
Genentech;
Infinity;
Morphotek;
Novartis; Pfizer;
Sanofi
1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin.
2010;60:277-300.
2. Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of
human sarcomas: insights into sarcoma biology. Cancer Res. 2005;65:9226-
9235.
3. Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the
mammalian target of rapamycin inhibitor ridaforolimus in patients with
advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30:78-84.
4. Chawla SP, Blay J, Ray-Coquard IL, et al. Results of the phase III,
placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus
(R) as maintenance therapy in advanced sarcoma patients (pts)
following clinical benefit from prior standard cytotoxic chemotherapy (CT).
J Clin Oncol. 2011;29(suppl; abstr 10005).
5. Demetri GD, Chawla SP, Ray-Coquard I, et al. Exploratory analysis of
potential predictive markers to identify sensitive/responder sarcoma patients
with ridaforolimus in the phase 3 randomized placebo-controlled trial (SUC-
CEED). Poster presented at: Combined Meeting of the Connective Tissue
Oncology Society/Musculoskeletal Tumor Society; October 2011; Chicago, IL.
6. D’Adamo DR, Anderson SE, Albritton K, et al. Phase II study of
doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
J Clin Oncol. 2005;23:7135-7142.
7. Verschraegen CF, Arias-Pulido H, Lee SJ, et al. Phase IB study of the
combination of docetaxel, gemcitabine, and bevacizumab in patients with
advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol.
Epub 2011 Jul 11.
8. Agulnik M, Okuno SH, Von Mehren M, et al. An open-label multicenter
phase II study of bevacizumab for the treatment of angiosarcoma. J Clin
Oncol. 2009;27:XXX (suppl; abstr 10522).
9. Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in
patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133-
3140.
10. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of
sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
J Clin Oncol. 2009;27:3154-3160.
11. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase
angiogenesis inhibitor, in patients with relapsed or refractory advanced soft
tissue sarcoma: a phase II study from the European organisation for research
and treatment of cancer-soft tissue and bone sarcoma group (EORTC study
62043). J Clin Oncol. 2009;27:3126-3132.
12. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in
relapsed and unresectable high-grade osteosarcoma after failure of standard
multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23:
508-516.
13. Van Der Graaf WT, Blay J, Chawla SP, et al. PALETTE: a randomized,
double-blind, phase III trial of pazopanib versus placebo in patients with
soft-tissue sarcoma whose disease has progressed during or following prior
chemotherapy—an EORTC STBSG Global Network Study (EORTC 62072).
J Clin Oncol. 2011;29 (suppl; abstr LBA002).
14. Gardner K, Judson I, Leahy M, et al. Activity of cediranib, a highly
potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma.
J Clin Oncol. 2009;27:15s (suppl; abstr 10523)
15. Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar
soft part sarcoma; evidence of a direct antitumor effect. Ann Oncol. 2011;22:
1682-1690.
16. Stacchiotti S, Negri T, Palassini E, et al. Sunitinib malate and figitu-
656
REFERENCES
Novartis;
Ziopharm
Oncology
Research
Funding
ARIAD; Novartis;
Ziopharm
Oncology
Pfizer; Roche
ArQule;
Genentech;
Prolexys
RIEDEL, MAKI, AND WAGNER
Expert
Testimony
Other
Remuneration
mumab in solitary fibrous tumor; patterns and molecular bases of tumor
response. Mol Cancer Ther. 2010;9:1286-1297.
17. Park MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and
bevacizumab in the treatment of locally advanced, recurrent, and metastatic
hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011;117:
4939-4947.
18. Miriuka SG, Rao V, Peterson M, et al. mTOR inhibition induces
endothelial progenitor cell death. Am J Transplant. 2006;6:2069-2079.
19. Dancey JE, Monzon J. Ridaforolimus: a promising drug in the treatment
of soft-tissue sarcoma and other malignancies. Future Oncol. 2011;7:
827-839.
20. Baker LH, Rowinsky EK, Mendelson D, et al. Randomized, phase II
study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in
patients with advanced soft tissue sarcoma. J Clin Oncol. 2008;26:5583-5588.
21. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic
and translational study of the novel vascular targeting agent combretastatin
a-4 phosphate on a single-dose intravenous schedule in patients with advanced
cancer. Cancer Res. 2002;62:3408-3416.
22. Bilenker JH, Flaherty KT, Rosen M, et al. Phase I trial of combretastatin
a-4 phosphate with carboplatin. Clin Cancer Res. 2005;11:1527-1533.
23. van Valen F, Winkelmann W, Jurgens H. Type I and type II insulin-like
growth factor receptors and their function in human Ewing’s sarcoma cells. J
Cancer Res Clin Oncol. 1992;118:269-275.
24. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic,
and pharmacodynamic study of AMG 479, a fully human monoclonal
antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27:5800-
5807.
25. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics,
and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-
751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion
cohort study. Lancet Oncol. 2010;11:129-135.
26. Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic
study of cixutumumab in pediatric patients with refractory solid
tumors and Ewing sarcoma: a report from the Children’s Oncology Group.
J Clin Oncol. 2012;30:256-262.
27. Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of
the anti-insulin-like growth factor type 1 receptor antibody figitumumab
in patients with refractory Ewing sarcoma. J Clin Oncol. 2011;29:4534-
4540.
28. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to
the insulin-like growth factor 1 receptor, in patients with recurrent or refractory
Ewing sarcoma family of tumors: Results of a phase II Sarcoma Alliance for
Research through Collaboration study. J Clin Oncol. 2011;29:4541-4547.
29. Huang F, Greer A, Hurlburt W, et al. The mechanisms of differential
sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924)
and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 2009;
69:161-170.
30. Potratz JC, Saunders DN, Wai DH, et al. Synthetic lethality screens
reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor
inhibitor activity in childhood sarcomas. Cancer Res. 2010;70:8770-8781.
31. Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/
human epidermal growth factor receptor 2 heterodimerization contributes to
trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65:11118-
11128.
32. Del Valle L, Wang JY, Lassak A, et al. Insulin-like growth factor I